Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.
The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.

Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Core to Synairgen’s business strategy is the realisation of value via licensing transactions – as demonstrated through the out-licensing of SNG001 to AstraZeneca in 2014 in a deal worth up to $232m plus royalties.

(AIM:SNG).

http://www.synairgen.com/

Shares - Analysts do not rule out the possibility of AstraZeneca making a bid for Synairgen to avoid of paying the huge milestone and royalty payments it would incur if the drug reaches the market.

Interim Results
RNS
RNS Number : 1708Z
Synairgen plc
16 September 2015



Press release

Synairgen plc

('Synairgen' or the 'Company')



Interim results for the six months ended 30 June 2015



~ Progress continued on track with AZD9412 and Pharmaxis collaboration underway ~



Southampton, UK - 16 September 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 June 2015.



Operational highlights (including post period-end)

In July, AstraZeneca commenced its Phase IIa study of AZD9412 (inhaled interferon beta, developed by Synairgen and formerly known as SNG001). The study population will comprise patients with severe asthma, building on the clinical data from Synairgen's exploratory Phase lla trial in moderate to severe asthma, which showed that difficult to treat asthma patients appeared to derive most benefit from this therapy
Continued screening of new development opportunities using Synairgen's proprietary "BioBank" platform, leveraging Synairgen's world-class founder and respiratory drug discovery and development expertise
Research collaboration signed with Pharmaxis to develop a selective inhibitor of the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF)


Financial highlights

Research and development expenditure for the period was reduced to £0.48 million (H1 2014: £1.27 million) due to AstraZeneca having taken on the development costs of the interferon beta programme after the out-licensing in June 2014
Loss after tax for the period of £0.91 million (H1 2014: profit of £1.90 million)
Cash and deposit balances of £8.73 million at 30 June 2015 (30 June 2014: £6.08 million)


Richard Marsden, CEO of Synairgen, commented:



"During the period, Synairgen has been focused on working with AstraZeneca to support the start of the Phase IIa trial in AZD9412, which has now commenced and we look forward to updating you with the results.



We have also devoted significant resource to assessing and bringing new programmes into the company and we are delighted to have achieved the first of these, the recently announced collaboration with Pharmaxis in the important indication of Idiopathic Pulmonary Fibrosis."





-Ends-

Who Should Attend?Date:

Tuesday 12th April 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by: